Skip to content
DataLookout
Menu

NCT07889349

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change.

  1. Notable Recruitment opened
    • Start date changed from estimate of Nov 2026 to Nov 9, 2026
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Adverse events (AEs)
Timeframe: From pre-dose to 36 days post-dose.

Secondary (9)

Serum concentration of SHR-3201 after single-dose administration
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
Time to peak concentration (Tmax)
Peak concentration (Cmax)
Elimination half-life (T1/2)
Show 4 moreShow less
Clearance (CL)
Steady-state volume of distribution (Vss)
Bioavailability of SHR-3201 following subcutaneous administration
Incidence of anti-drug antibodies (ADA)

Arms and interventions

Dose 1 Group: SHR-3201 + PlaceboExperimental

SHR-3201, SHR-3201 Placebo, in Dose 1.

Dose 2 Group: SHR-3201 + PlaceboExperimental

SHR-3201, SHR-3201 Placebo, in Dose 2.

Dose 3 Group: SHR-3201 + PlaceboExperimental

SHR-3201, SHR-3201 Placebo, in Dose 3.

Dose 4 Group: SHR-3201 + PlaceboExperimental

SHR-3201, SHR-3201 Placebo, in Dose 4.

Dose 5 Group: SHR-3201 + PlaceboExperimental

SHR-3201, SHR-3201 Placebo, in Dose 5.

Drugs: SHR 3201 Injection, SHR 3201 Placebo.

Sites

1 site in 1 country

  • The First Affiliated Hospital of University of Science and Technology of ChinaHefei, Anhui, China